Ionis Pharmaceuticals, Inc. IONS R3KPHARMA
Company Overview
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Why Investors Should Care
Revenue has grown at a 13.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $943.71M (+33.8% YoY); net profit $-381.39M.
- Trailing 12 Months Year-on-year growth — revenue -40.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 13.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 13.65% |
| 1 Year: | -40.70% |
Stock Price Performance
| 1 Year: | +31.58% |
| 6 Months: | -24.75% |
| 3 Months: | -22.89% |
| 1 Month: | +0.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.35 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 13.7% over 5 years.
CONS
- Trading 34.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IONS Ionis Pharmaceuticals, Inc. R3KPHARMA | 56.71 | -16.30 | $9.42B | 0.00% | -13.92% | -105.50% | 13.65% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 115.80M | 112.27M | 118.31M | - | 144.42M | 117.75M | 145.40M | - | 297.21M | 163.81M | 167.89M | - | 133.37M | 145.54M | 160.08M | - | 111.61M | 125.75M | 133.09M | - | 141.92M | 133.79M | 159.77M | - | 130.52M | 188.41M | 144.21M | - | 119.50M | 225.25M | 133.81M | - | 131.61M | 452.05M | 156.72M | - | 246.09M | 267.95M |
| Operating Income | 16.11M | 41.16M | 19.48M | 6.45M | 11.31M | -6.20M | -3.30M | -50.28M | -18.57M | 10.78M | 121.53M | -18.83M | 2.52M | 260.65M | -61.13M | -51.75M | -36.54M | -22.66M | -91.97M | -72.97M | -85.85M | 220.60M | -57.50M | -85.51M | -59.15M | -208.02M | -114.15M | -90.19M | -143.26M | -6.12M | -149.51M | -66.09M | -148.66M | -110.82M | -146.86M | 139.82M | -160.18M | -214.46M | -117.42M | -102.29M |
| Net Income | 7.35M | 25.86M | 8.96M | -3.08M | -2.61M | -2.92M | -1.42M | -40.36M | -4.56M | 320.08M | 84.44M | -876.00K | 26.16M | 184.41M | -39.63M | -25.64M | -24.47M | -354.53M | -89.87M | -80.88M | -82.47M | 224.61M | -65.17M | -105.14M | -46.99M | -52.43M | -124.32M | -85.29M | -147.41M | -9.26M | -142.80M | -66.27M | -140.48M | -104.35M | -146.94M | 123.55M | -128.61M | -229.39M | -92.53M | -114.65M |
| Diluted EPS | 0.06 | 0.21 | 0.07 | -0.02 | -0.02 | -0.03 | -0.01 | -0.29 | -0.03 | 2.21 | 0.62 | -0.01 | 0.18 | 1.28 | -0.28 | -0.18 | -0.18 | -2.54 | -0.64 | -0.57 | -0.58 | 1.41 | -0.46 | -0.74 | -0.33 | -0.37 | -0.87 | -0.60 | -1.03 | -0.06 | -0.98 | -0.45 | -0.95 | -0.66 | -0.93 | 0.70 | -0.80 | -1.41 | -0.56 | -0.69 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 107.19M | 121.60M | 108.47M | 99.09M | 102.05M | 147.28M | 214.16M | 283.70M | 372.78M | 514.18M | 599.67M | 1.12B | 729.26M | 810.46M | 587.37M | 787.65M | 705.14M | 943.71M |
| Operating Income | -13.06M | -27.54M | -48.36M | -71.10M | -68.92M | -51.67M | -47.73M | -75.76M | -20.16M | 31.05M | -61.37M | 365.88M | -172.08M | -30.19M | -410.19M | -353.73M | -475.08M | -381.68M |
| Net Income | -18.17M | 155.07M | -61.25M | -84.80M | -65.48M | -60.64M | -38.98M | -88.28M | -60.40M | 346.00K | 273.74M | 278.14M | -444.26M | -28.60M | -269.72M | -366.29M | -453.90M | -381.39M |
| Diluted EPS | -0.19 | 1.58 | -0.62 | -0.85 | - | - | - | -0.74 | -0.50 | 0.15 | 2.07 | 1.90 | -3.18 | -0.20 | -1.90 | -2.56 | -3.04 | -2.38 |
| R&D Expense | 106.44M | 134.62M | 145.16M | 153.10M | 154.60M | 173.70M | 238.90M | 319.50M | 340.40M | 372.50M | 411.90M | 461.50M | 531.00M | 638.20M | - | 899.62M | 901.53M | 915.62M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 657.18M | 550.48M | 484.89M | 545.69M | 847.16M | 955.81M | 947.90M | 912.47M | 1.32B | 2.67B | 3.23B | 2.39B | - | 2.53B | 2.99B | 3.00B | 3.52B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.20B | 2.64B | 2.62B | 2.99B |
| Cash & Equivalents | 138.61M | 223.99M | 105.25M | 70.05M | 65.48M | 124.48M | 159.97M | 143.00M | 128.80M | 84.69M | 129.63M | 278.82M | 683.29M | 397.66M | - | 276.47M | 399.27M | 242.08M | 372.26M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.03M | 7.44M | 12.51M | 10.05M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.54M | 97.78M | 92.19M | 66.06M |
| Total Liabilities | - | - | 355.12M | 305.94M | 313.46M | 362.92M | 468.77M | 698.03M | 747.11M | 812.90M | 957.49M | 1.48B | 1.55B | 1.65B | - | 1.96B | 2.60B | 2.42B | 3.03B |
| Current Liabilities | - | - | 111.44M | 105.89M | 76.11M | 74.32M | 97.81M | 115.33M | 148.88M | 133.78M | 243.61M | 280.29M | 273.00M | 598.90M | - | 311.56M | 448.09M | 309.32M | 781.57M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.18B | 1.23B | 1.25B | 1.35B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.37B | 1.45B | 1.42B | 2.06B |
| Total Equity | 59.59M | 147.38M | 291.72M | 244.54M | 171.43M | 182.77M | 378.39M | 257.78M | 200.79M | 99.56M | 281.01M | 1.05B | 1.47B | 743.28M | - | 572.89M | 386.69M | 588.35M | 489.09M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 142.06M | 144.34M | 157.91M | 163.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 212.03M | -108.44M | -63.59M | -114.80M | - | - | - | 21.12M | -112.11M | 174.15M | 602.91M | 345.63M | 35.89M | 30.80M | -274.37M | -307.51M | -500.95M | -268.58M |
| Investing Cash Flow | -234.25M | -212.29M | 23.69M | 110.90M | - | - | - | -60.05M | 56.60M | -358.29M | -929.56M | -41.27M | 274.48M | 194.91M | -262.64M | -214.13M | -134.03M | -277.78M |
| Financing Cash Flow | 107.58M | 202.00M | 4.70M | -672.00K | - | - | - | 24.73M | 11.39M | 229.09M | 475.87M | 100.02M | -596.61M | 245.93M | -55.30M | 644.08M | 478.06M | 675.84M |
| Capital Expenditure | -13.66M | -13.41M | -13.24M | -10.20M | -1.48M | -1.55M | -7.52M | -7.69M | -7.11M | -34.76M | -13.61M | -30.91M | -35.12M | -11.96M | -15.72M | -23.80M | -45.28M | -51.44M |
| Free Cash Flow | 198.37M | -121.86M | -76.83M | -125.00M | - | - | - | 13.43M | -119.21M | 139.38M | 589.30M | 314.72M | 772.00K | 18.84M | -290.09M | -331.32M | -546.23M | -320.03M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | 0 | 0 | 34.40M | 90.55M | 0 | 0 | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -12.2% | -22.6% | -44.6% | -71.8% | -67.5% | -35.1% | -22.3% | -26.7% | -5.4% | 6.0% | -10.2% | 32.6% | -23.6% | -3.7% | -69.8% | -44.9% | -67.4% | -40.4% |
| Net Margin % | -17.0% | 127.5% | -56.5% | -85.6% | -64.2% | -41.2% | -18.2% | -31.1% | -16.2% | 0.1% | 45.6% | 24.8% | -60.9% | -3.5% | -45.9% | -46.5% | -64.4% | -40.4% |
| ROE % | -12.3% | 53.2% | -25.0% | -49.5% | -35.8% | -16.0% | -15.1% | -44.0% | -60.7% | 0.1% | 26.1% | 18.9% | -59.8% | - | -47.1% | -94.7% | -77.1% | -78.0% |
| ROCE % | - | -5.0% | -10.9% | -17.4% | -14.6% | -6.9% | -5.7% | -9.5% | -2.6% | 2.9% | -2.6% | 12.4% | -9.6% | - | -18.5% | -13.9% | -17.6% | -13.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.82% | 24.63M | $1.09B |
| 2 | Capital World Investors | 13.04% | 21.67M | $962.98M |
| 3 | Blackrock Inc. | 6.44% | 10.70M | $475.72M |
| 4 | Vanguard Portfolio Management LLC | 4.73% | 7.86M | $349.28M |
| 5 | Wellington Management Group, LLP | 4.60% | 7.65M | $340.03M |
| 6 | Vanguard Capital Management LLC | 4.34% | 7.21M | $320.48M |
| 7 | Two Sigma Investments, LP | 3.76% | 6.25M | $277.85M |
| 8 | Royal Bank of Canada | 3.72% | 6.18M | $274.75M |
| 9 | State Street Corporation | 2.61% | 4.33M | $192.64M |
| 10 | T. Rowe Price Investment Management, Inc. | 2.38% | 3.96M | $175.95M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IONS
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBaTzJ3eUlOcjh3M0t2YV9HelJsdFFhOHZSQVpnajVEd0FQRG9ZOU1INTQ2bVpIYU9laEhwVzZKZjg3Q0lHUkg1ZlRKR1lfbGRt?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Why Did Ionis Pharmaceuticals (IONS) Stock Drop After Its Latest Update? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQWFlnSndsbktFcGxkZkdNTXVsZDVSV0VmRzJuV244cC1PTm42VTk5Y1BDMnJ0b1BuOUd1ZGlOSDBabEdRNDExOGxxcm9wVzYwOG9NZzhydzFkSGJmQ0Y1dHdRYWdPRjh4cXlsRWRFVUV4d1BKOHYyR1dGUmh1ajZOZmZDZWkxZTJOTzh0UD…
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Evaluating A 51.72% Upside Potential - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNMF9RS2hjMUYwcW5zT1p4RnBfS0RXQWk5Y1R4VndpOWR2eFVWa2pYTE9UMWVRaWUzaldmUjF4Y0tHcThRaVNZWTBiOUxKQzRORWNKQnNLODRaaldRcEF2cjRqOFNINFN2Q1Z1U1J2Tl95WldhTkpqeWRLNGdoTEJDY3VJckpjaWR0VWdrZU…
IONS Maintained by HC Wainwright & Co. -- Price Target Lowered to $100 - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQdFI2LVZaUWZYREdKWWMtTWNRaV9sYzluYjlpWXN6djdBc0JqVlBtYTBZOUNlZUhnZVFsZ0dSRkI4T3Y1S1pab3RubENmeXlzSk01T1hDLWtBZFlELUhMeXlLXzBkaEJRUkE1cGhISl9vbWxSX3M3RGRhYzBxcE9ObU83eFNvekZNNkVNbU…
NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQQ29QRS1XUThod3cxN2c4M0E5cjZlSGdZWWhfTjlYU25VV3djZGRNSlg4b0FiRVF1OWlITDdUbll2akR6T3BWN0NQc2laVjE4T3daTXgtSzNtOTBnM1NpSTE1Q3RJT1VjbzBzcFREd3o4MHlHeHhhcllrR0ZKSXhYbTMzcno1dklGZHlwTk…
Ionis Pharmaceuticals (IONS) Sets Up New Cardiology Data, Is The Stock Still Undervalued? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxPUnRhdUFPN1NWVHluaEh5Nk1SdnFIOHR3TkpuU3lMZTZqUTBZOXdlZk4wWTdsS3RWb0xhczJBeFZnNG5GTFJYbFpXTzJ5aE1MRXoxS3FDVTRfWkFNYlR6ek5jMmUwaHZmTzI2R0Y4TXZrZEVCNC0zdkVIZk1nTGl3S1FTODJRM2x4R2VoRn…
IONS — Frequently Asked Questions
What is the current share price of Ionis Pharmaceuticals, Inc. (IONS)?
As of 2026-09-19 21:16 PDT, Ionis Pharmaceuticals, Inc. (IONS) trades at $56.71 on NasdaqGS. Its 52-week range is $41.82 to $86.50.
What is the market capitalisation of IONS?
Ionis Pharmaceuticals, Inc. (IONS) has a market capitalisation of $9.42B on NasdaqGS.
What is the P/E ratio of IONS?
IONS trades at a trailing price-to-earnings (P/E) ratio of -16.30. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 16.74.
What is the return on equity (ROE) of IONS?
IONS has a return on equity (ROE) of -105.50%. Its return on capital employed (ROCE) is -13.92%.
Is IONS a good stock to buy?
This page provides a data-driven analysis of Ionis Pharmaceuticals, Inc. (IONS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.